CORONA
CORONA REMEDIES LIMITED
CORONA REMEDIES LIMITED (CORONA) Stock Analysis & Case Study
Is CORONA a good buy? The data-driven verdict.
CORONA REMEDIES LIMITED (CORONA) trades at ₹2,059,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, CORONA REMEDIES LIMITED (CORONA) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 59.3× earnings, ROE of 29.5%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
CORONA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How CORONA ranks against the 2,373 companies in our screener
- CORONA's market cap of 12,592 Cr ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's book value of ₹122 ranks in the 58th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's promoter holding of 69.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's 3-year profit (PAT) growth of 33.0% ranks in the 72nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's 3-year revenue growth of 17.0% ranks in the 67th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's debt-to-equity ratio of 0.22x is lower than 60% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is CORONA overvalued? CORONA P/E vs peers
CORONA trades at 59.3× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
The bull case for CORONA
- CORONA's return on equity of 29.5% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- CORONA's return on capital employed of 33.3% ranks in the 94th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
The bear case & risks
- CORONA's P/E of 59.3x is lower than 21% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 16.9× price-to-book means most of the value is intangible/expectations, not assets on the books.
CORONA Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. CORONA scores 6/8, mixed financial health.
CORONA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy CORONA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 27.29% | 3.7× |
| Groww | 27.31% | 3.7× |
| Dhan | 27.29% | 3.7× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 27.31% | 3.7× |
| PocketfulCHEAPEST | 27.13% | 3.7× |
| Fyers | 27.78% | 3.6× |
| Anand Rathi | 27.29% | 3.7× |
| Share India | 27.16% | 3.7× |
Compare every broker on the CORONA MTF page.
About CORONA REMEDIES LIMITED: sector, index & market-cap context
CORONA REMEDIES LIMITED (CORONA) is a small-cap NSE-listed company, with a market capitalisation of ₹12,592 Cr. See more stocks on our screener.
How the CORONA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of CORONA REMEDIES LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
CORONA analysis, FAQs
Is CORONA REMEDIES LIMITED (CORONA) a good buy?
On the numbers, CORONA REMEDIES LIMITED (CORONA) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 59.3× earnings, ROE of 29.5%. This is a data snapshot for research, not investment advice.
Is CORONA overvalued or undervalued?
CORONA trades at 59.3× earnings, expensive versus the ~22× long-run Nifty average.
What is the bull case for CORONA?
CORONA's return on equity of 29.5% ranks in the 93rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. CORONA's return on capital employed of 33.3% ranks in the 94th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in CORONA?
CORONA's P/E of 59.3x is lower than 21% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 16.9× price-to-book means most of the value is intangible/expectations, not assets on the books.